Case:,Unnamed: 1,SE21-1318_AMDL2021_Hi5-01_Hi5_AGXTHSv2,Unnamed: 3,Unnamed: 4,Unnamed: 5,Unnamed: 6,Unnamed: 7,Unnamed: 8,Unnamed: 9,Unnamed: 10,Unnamed: 11,Unnamed: 12,Unnamed: 13,Unnamed: 14,Unnamed: 15,Unnamed: 16,Unnamed: 17,Unnamed: 18,Unnamed: 19,Unnamed: 20,Unnamed: 21,Unnamed: 22,Unnamed: 23,Unnamed: 24,Unnamed: 25,Unnamed: 26,Unnamed: 27,Unnamed: 28,Unnamed: 29,Unnamed: 30,Unnamed: 31,Unnamed: 32,Unnamed: 33,Unnamed: 34,Unnamed: 35,Unnamed: 36,Unnamed: 37,Unnamed: 38,Unnamed: 39,Unnamed: 40,Unnamed: 41,Unnamed: 42,Unnamed: 43,Unnamed: 44,Unnamed: 45,Unnamed: 46,Unnamed: 47,Unnamed: 48,Unnamed: 49,Unnamed: 50,Unnamed: 51,Unnamed: 52,Unnamed: 53,Unnamed: 54,Unnamed: 55,Unnamed: 56,Unnamed: 57,Unnamed: 58,Unnamed: 59,Unnamed: 60,Unnamed: 61,Unnamed: 62,Unnamed: 63,Unnamed: 64,Unnamed: 65,Unnamed: 66,Unnamed: 67,Unnamed: 68,Unnamed: 69,Unnamed: 70,Unnamed: 71,Unnamed: 72,Unnamed: 73,Unnamed: 74,Unnamed: 75,Unnamed: 76,Unnamed: 77,Unnamed: 78,Unnamed: 79,Unnamed: 80,Unnamed: 81,Unnamed: 82,Unnamed: 83,Unnamed: 84,Unnamed: 85,Unnamed: 86,Unnamed: 87,Unnamed: 88,Unnamed: 89,Unnamed: 90,Unnamed: 91,Unnamed: 92,Unnamed: 93,Unnamed: 94,Unnamed: 95,Unnamed: 96,Unnamed: 97,Unnamed: 98,Unnamed: 99,Unnamed: 100,Unnamed: 101,Unnamed: 102,Unnamed: 103,Unnamed: 104,Unnamed: 105,Unnamed: 106,Unnamed: 107,Unnamed: 108,Unnamed: 109,Unnamed: 110,Unnamed: 111,Unnamed: 112,Unnamed: 113,Unnamed: 114,Unnamed: 115,Unnamed: 116,Unnamed: 117,Unnamed: 118,Unnamed: 119,Unnamed: 120,Unnamed: 121,Unnamed: 122,Unnamed: 123,Unnamed: 124,Unnamed: 125,Unnamed: 126,Unnamed: 127,Unnamed: 128,Unnamed: 129,Unnamed: 130,Unnamed: 131,Unnamed: 132,Unnamed: 133,Unnamed: 134,Unnamed: 135,Unnamed: 136,Unnamed: 137,Unnamed: 138,Unnamed: 139,Unnamed: 140,Unnamed: 141,Unnamed: 142,Unnamed: 143,Unnamed: 144,Unnamed: 145,Unnamed: 146,Unnamed: 147,Unnamed: 148,Unnamed: 149,Unnamed: 150,Unnamed: 151,Unnamed: 152,Unnamed: 153,Unnamed: 154,Unnamed: 155,Unnamed: 156,Unnamed: 157,Unnamed: 158,Unnamed: 159,Unnamed: 160,Unnamed: 161,Unnamed: 162,Unnamed: 163,Unnamed: 164,Unnamed: 165,Unnamed: 166,Unnamed: 167,Unnamed: 168,Unnamed: 169,Unnamed: 170,Unnamed: 171,Unnamed: 172,Unnamed: 173,Unnamed: 174,Unnamed: 175
Created by,,UHN-CLG Annotation v0.9,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
User,,user_placeholder,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
Date and time,,2021-04-15 15:14:23.125000,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
Genome build,,GRCh37/hg19,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
IGV,,Open IGV and then click here to load BAM,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
Annotation Sources,,gnomAD,gnomAD release 2.11,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,,ESP6500,Variants in the ESP6500SI-V2 dataset of the exome sequencing project (ESP),,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,,1000Genomes,1000 Genomes 2015,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,,ExAC,ExAC release 0.3,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,,COSMIC,COSMIC release v70,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,,dbSNP,dbSNP build 147,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,,ClinVar,NCBI ClinVar 20190305,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
Tumour site:,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
Histological diagnosis:,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
Primary/clinical history:,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
Disease:,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
Tech 1:,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
Tech 2:,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
SortOrder,Chr,Start,End,Ref,Alt,Gene,Transcript,cDNA,Protein,Depth,VAF,IGV,Tech 1,Tech 2,Remove from review?,Observed_panel,Assessment,Report,Annotation,Charge Tech,GQ,Judgement,Callers,Observed_panel,VAF_panel,Case_list,Observed_run,VAF_run,StrandBias,GA4GH,AMDL_Reportable,Exon,Func.UHNCLGGene,InSilicoDamaging,InSilicoBenign,CancerHotSpot,VarKB,JAX_gene,JAX_variant,Gene.UHNCLGGene,GeneDetail.UHNCLGGene,ExonicFunc.UHNCLGGene,AAChange.UHNCLGGene,Func.refGene,Gene.refGene,GeneDetail.refGene,ExonicFunc.refGene,AAChange.refGene,Func.knownGene,Gene.knownGene,GeneDetail.knownGene,ExonicFunc.knownGene,AAChange.knownGene,genomicSuperDups,AF,AF_popmax,AF_male,AF_female,AF_raw,AF_afr,AF_sas,AF_amr,AF_eas,AF_nfe,AF_fin,AF_asj,AF_oth,non_topmed_AF_popmax,non_neuro_AF_popmax,non_cancer_AF_popmax,controls_AF_popmax,avsift,cosmic70,CLNALLELEID,CLNDN,CLNDISDB,CLNREVSTAT,CLNSIG,avsnp144,snp138NonFlagged,Polyphen2_HDIV_score,Polyphen2_HDIV_pred,Polyphen2_HVAR_score,Polyphen2_HVAR_pred,VEST3_score,CADD_raw,CADD_phred,DANN_score,phyloP7way_vertebrate,phastCons7way_vertebrate,SIFT_score,SIFT_converted_rankscore,SIFT_pred,LRT_score,LRT_converted_rankscore,LRT_pred,MutationTaster_score,MutationTaster_converted_rankscore,MutationTaster_pred,MutationAssessor_score,MutationAssessor_score_rankscore,MutationAssessor_pred,FATHMM_score,FATHMM_converted_rankscore,FATHMM_pred,PROVEAN_score,PROVEAN_converted_rankscore,PROVEAN_pred,MetaSVM_score,MetaSVM_rankscore,MetaSVM_pred,MetaLR_score,MetaLR_rankscore,MetaLR_pred,M-CAP_score,M-CAP_rankscore,M-CAP_pred,MutPred_score,MutPred_rankscore,fathmm-MKL_coding_score,fathmm-MKL_coding_rankscore,fathmm-MKL_coding_pred,Eigen_coding_or_noncoding,Eigen-raw,Eigen-PC-raw,GenoCanyon_score,GenoCanyon_score_rankscore,integrated_fitCons_score,integrated_fitCons_score_rankscore,integrated_confidence_value,GERP++_RS,GERP++_RS_rankscore,phyloP100way_vertebrate,phyloP100way_vertebrate_rankscore,phyloP20way_mammalian,phyloP20way_mammalian_rankscore,phastCons100way_vertebrate,phastCons100way_vertebrate_rankscore,phastCons20way_mammalian,phastCons20way_mammalian_rankscore,SiPhy_29way_logOdds,SiPhy_29way_logOdds_rankscore,Interpro_domain,GTEx_V6p_gene,GTEx_V6p_tissue,1000g2012apr_all,1000g2012apr_afr,1000g2012apr_amr,1000g2012apr_asn,1000g2012apr_eur,1000g2015aug_all,1000g2015aug_afr,1000g2015aug_amr,1000g2015aug_eas,1000g2015aug_eur,1000g2015aug_sas,esp6500siv2_all,ExAC_ALL,ExAC_AFR,ExAC_AMR,ExAC_EAS,ExAC_FIN,ExAC_NFE,ExAC_OTH,ExAC_SAS,CHROM,POS,ID,REF,ALT,QUAL,FILTER,INFO,FORMAT,DATA
1,chr1,43817961,43817961,C,T,MPL,NM_005373,c.1640C>T,p.Ala547Val,338,0.5947,IGV,,,,'2/293',,True,,,255,Exonic;VAF>=0.05;DP>=100,VarScan2,'2/293',0.5941;0.5944;0.5944;0.5947,SE21-1318_AMDL2021_Hi5-01_Hi5_AGXTHSv2;SE20-0964_VEN-264-ARC-1_Hi5_AGXTHSv2,'1/12',0.5947;0.5947;0.5947;0.5947,,,MPL;NM_005373.2;exon_11,exon11,exonic,,,,http://205.210.128.135:8000/gene/MPL/variant/p.Ala547Val/result#report,"Gene Role: Oncogene (PMID: 30606230);Highest Evidence Level: A;Highest Tier: I;MPL, MPL proto-oncogene, thrombopoietin receptor, binds the cytokine, thrombopoietin, to induce signaling of JAK2 and TYK2 to activate several signal transduction pathways to control blood cell development (PMID: 16834459, PMID: 28408900). MPL mutations are often found in myeloproliferative neoplasms (PMID: 27727468, PMID: 31858134, PMID: 31750750).",,MPL,,nonsynonymous SNV,MPL:NM_005373:exon11:c.C1640T:p.A547V,exonic,MPL,,nonsynonymous SNV,MPL:NM_005373:exon11:c.C1640T:p.A547V,exonic,MPL,,nonsynonymous SNV,MPL:uc001ciw.3:exon11:c.C1640T:p.A547V;MPL:uc009vwr.3:exon11:c.C1619T:p.A540V,,,,,,,,,,,,,,,,,,,0.1,,,,,,,rs572129852,,0.682,P,0.202,B,0.348,2.509,19.53,0.993,0.787,0.905,0.106,0.296,T,0.03,0.253,U,0.684,0.302,N,1.7,0.44,L,-1.6,0.822,D,-0.92,0.247,N,-0.243,0.766,T,0.416,0.763,T,0.204,0.87,D,0.337,0.327,0.856,0.445,D,c,-0.037,-0.025,1,0.489,0.421,0.056,0,3.67,0.411,2.63,0.459,-0.087,0.118,0.996,0.391,0.825,0.345,12.217,0.535,.,.,.,,,,,,0.000199681,,,,,0.001,,0.0002,0,0,0,0,0,0,0.0012,chr1,43817961,.,C,T,.,PASS,ADP=338;WT=0;HET=1;HOM=0;NC=0,GT:GQ:SDP:DP:RD:AD:FREQ:PVAL:RBQ:ABQ:RDF:RDR:ADF:ADR:FA,0/1:255:338:338:137:201:59.47%:3.5315E-80:69:56:103:34:155:46:0.5947
2,chr1,115256529,115256529,T,C,NRAS,NM_002524,c.182A>G,p.Gln61Arg,499,0.2685,IGV,,,,'3/293',,True,,,255,Exonic;VAF>=0.05;DP>=100,VarScan2,'3/293',0.011;0.2431;0.1742;0.2685,SE21-1318_AMDL2021_Hi5-01_Hi5_AGXTHSv2;SE20-0964_VEN-264-ARC-1_Hi5_AGXTHSv2;SE21-0060_Seraseq-ctDNA-1-200_Hi5_AGXTHSv2,'1/12',0.2685;0.2685;0.2685;0.2685,,,NRAS;NM_002524.4;exon_3,exon3,exonic,,,,http://205.210.128.135:8000/gene/NRAS/variant/p.Gln61Arg/result#report,"Gene Role: Oncogene (PMID: 30606230);Highest Evidence Level: A;Highest Tier: I;NRAS, NRAS proto-oncogene, GTPase, is a member of the family of small GTPase that when activated by growth factors, stimulates multiple effector pathways such as RAF and PI3K to promote cell proliferation and survival (PMID: 29524560). NRAS mutations have been observed in a variety of cancers including melanoma, thyroid, breast, ovary cancer, and leukemia (PMID: 29524560, PMID: 30154648, PMID: 28860801).","JAX variant ID 3220;Impact: missense;Protein Effect: loss of function;NRAS Q61R is a hotspot mutation that lies within a GTP-binding region of the Nras protein (UniProt.org). Q61R results in a loss of Nras GTPase function as indicated by increased GTP-bound Nras, which leads to activation of Mapk signaling in culture (PMID: 16818621).",NRAS,,nonsynonymous SNV,NRAS:NM_002524:exon3:c.A182G:p.Q61R,exonic,NRAS,,nonsynonymous SNV,NRAS:NM_002524:exon3:c.A182G:p.Q61R,exonic,NRAS,,nonsynonymous SNV,NRAS:uc009wgu.3:exon3:c.A182G:p.Q61R,,,,,,,,,,,,,,,,,,,0.04,"ID=COSM584;OCCURENCE=4(soft_tissue),3(ovary),4(endometrium),474(skin),7(breast),1(small_intestine),7(urinary_tract),7(adrenal_gland),1(liver),4(eye),2(pancreas),4(biliary_tract),49(large_intestine),5(central_nervous_system),49(NS),289(thyroid),12(lung),9(meninges),3(testis),69(haematopoietic_and_lymphoid_tissue)",28939,"Hepatocellular_carcinoma|Acute_myeloid_leukemia|Chronic_lymphocytic_leukemia|Renal_cell_carcinoma,_papillary,_1|Congenital_giant_melanocytic_nevus|Follicular_thyroid_carcinoma|Transitional_cell_carcinoma_of_the_bladder|Adrenocortical_carcinoma|Multiple_myeloma|Epidermal_nevus|Cutaneous_melanoma|Lung_adenocarcinoma|Non-small_cell_lung_cancer|Neoplasm_of_brain|Neoplasm_of_the_large_intestine|Malignant_melanoma_of_skin|Glioblastoma|Nasopharyngeal_Neoplasms|Malignant_neoplasm_of_body_of_uterus|Epidermal_nevus_syndrome|Adenocarcinoma_of_stomach|Ovarian_Serous_Cystadenocarcinoma|Neurocutaneous_melanosis|not_provided","Human_Phenotype_Ontology:HP:0001402,MedGen:C2239176,OMIM:114550,Orphanet:ORPHA88673,SNOMED_CT:187769009,SNOMED_CT:25370001|Human_Phenotype_Ontology:HP:0004808,MeSH:D015470,MedGen:C0023467,OMIM:601626,Orphanet:ORPHA519,SNOMED_CT:17788007|Human_Phenotype_Ontology:HP:0005550,MeSH:D015451,MedGen:C0023434,OMIM:151400,Orphanet:ORPHA67038,SNOMED_CT:277473004,SNOMED_CT:51092000|Human_Phenotype_Ontology:HP:0005584,MeSH:D002292,MedGen:C0007134,OMIM:605074,Orphanet:ORPHA217071,SNOMED_CT:41607009|Human_Phenotype_Ontology:HP:0005600,MedGen:C1842036,OMIM:137550,Orphanet:ORPHA626|Human_Phenotype_Ontology:HP:0006731,MedGen:C4225426,OMIM:188470|Human_Phenotype_Ontology:HP:0006740,MedGen:C0279680|Human_Phenotype_Ontology:HP:0006744,MeSH:D018268,MedGen:C0206686,Orphanet:ORPHA1501|Human_Phenotype_Ontology:HP:0006775,MeSH:D009101,MedGen:C0026764,OMIM:254500,Orphanet:ORPHA29073,SNOMED_CT:109989006,SNOMED_CT:55921005|Human_Phenotype_Ontology:HP:0010816,MedGen:C0334082,OMIM:162900,Orphanet:ORPHA35125,SNOMED_CT:25201003|Human_Phenotype_Ontology:HP:0012056,MeSH:D008545,MedGen:C0025202|Human_Phenotype_Ontology:HP:0030078,MeSH:C538231,MedGen:C0152013|Human_Phenotype_Ontology:HP:0030358,MeSH:D002289,MedGen:C0007131,SNOMED_CT:254637007|Human_Phenotype_Ontology:HP:0030692,MeSH:D001932,MedGen:C0006118,SNOMED_CT:126952004|Human_Phenotype_Ontology:HP:0100834,MeSH:D015179,MedGen:C0009404,SNOMED_CT:126837005|MeSH:C562393,MedGen:C0151779,SNOMED_CT:93655004|MeSH:D005909,MedGen:C0017636,Orphanet:ORPHA360,SNOMED_CT:63634009|MeSH:D009303,MedGen:C0027439|MedGen:C0153574,Orphanet:ORPHA213569|MedGen:C0265318,OMIM:163200,SNOMED_CT:239112008|MedGen:C0278701|MedGen:C0279663|MedGen:C0544862,OMIM:249400,Orphanet:ORPHA2481|MedGen:CN517202","criteria_provided,_multiple_submitters,_no_conflicts",Pathogenic,rs11554290,,0.214,B,0.304,B,0.915,3.571,23.1,0.997,0.991,1,0.029,0.457,D,0,0.537,U,1,0.81,D,3.275,0.903,M,-1.75,0.835,D,-3.38,0.667,D,0.292,0.874,D,0.595,0.855,D,0.112,0.791,D,0.752,0.883,0.986,0.849,D,c,0.461,0.513,1,0.747,0.722,0.854,0,5.08,0.682,7.911,0.868,1.061,0.807,1,0.715,1,0.888,15.013,0.711,P-loop containing nucleoside triphosphate hydrolase|Small GTP-binding protein domain,.,.,,,,,,,,,,,,,,,,,,,,,chr1,115256529,.,T,C,.,PASS,ADP=499;WT=0;HET=1;HOM=0;NC=0,GT:GQ:SDP:DP:RD:AD:FREQ:PVAL:RBQ:ABQ:RDF:RDR:ADF:ADR:FA,0/1:255:501:499:364:134:26.85%:1.4353E-45:60:59:247:117:101:33:0.2685
3,chr2,60688440,60688440,A,C,BCL11A,NM_022893,c.1607T>G,p.Val536Gly,132,0.0606,IGV,,,,'13/293',,True,,,24,Exonic;VAF>=0.05;DP>=100,VarScan2,'13/293',0.0132;0.0365;0.0407;0.1,SE20-1333_DIVA-180-BX-1_Hi5_AGXTHSv2;SE21-0007_EMQN-REF-01_Hi5_AGXTHSv2;SE21-0609_DIVA-208-ARC-1_Hi5_AGXTHSv2;SE21-0946_VEN-351-ARC-1_Hi5_AGXTHSv2;SE21-0060_Seraseq-ctDNA-1-200_Hi5_AGXTHSv2;SE21-0028_EMQN-REF-22_Hi5_AGXTHSv2;SE21-0029_EMQN-REF-23_Hi5_AGXTHSv2;SE21-0334_DIVA-414-BX-1_Hi5_AGXTHSv2;SE21-0232_DIVA-418-BX-2_Hi5_AGXTHSv2;SE21-0008_EMQN-REF-02_Hi5_AGXTHSv2;SE21-0027_EMQN-REF-21_Hi5_AGXTHSv2;SE21-0061_Seraseq-ctDNA-WT_Hi5_AGXTHSv2;SE21-1318_AMDL2021_Hi5-01_Hi5_AGXTHSv2,'2/12',0.0606;0.0653;0.0653;0.07,,,BCL11A;NM_022893.3;exon_4,exon4,exonic,,"Benign (5/7): MutationAssessor, Polyphen2_HDIV, Polyphen2_HVAR, SIFT, PROVEAN",,http://205.210.128.135:8000/gene/BCL11A/variant/p.Val536Gly/result#report,,,BCL11A,,nonsynonymous SNV,BCL11A:NM_022893:exon4:c.T1607G:p.V536G,exonic,BCL11A,,nonsynonymous SNV,BCL11A:NM_018014:exon4:c.T1607G:p.V536G;BCL11A:NM_022893:exon4:c.T1607G:p.V536G,exonic,BCL11A,,nonsynonymous SNV,BCL11A:uc002sad.1:exon3:c.T1151G:p.V384G;BCL11A:uc002saf.1:exon3:c.T1505G:p.V502G;BCL11A:uc010ypj.2:exon3:c.T1505G:p.V502G;BCL11A:uc002sab.3:exon4:c.T1607G:p.V536G;BCL11A:uc002sae.1:exon4:c.T1607G:p.V536G;BCL11A:uc010ypi.2:exon6:c.T614G:p.V205G,,,,,,,,,,,,,,,,,,,0.03,,,,,,,,,0.006,B,0.005,B,0.351,0.692,8.773,0.889,0.126,0.996,0.02,0.614,D,0.013,0.29,U,1,0.81,D,0.205,0.094,N,3.14,0.079,T,-0.01,0.09,N,-0.979,0.352,T,0.013,0.051,T,0.007,0.184,T,0.625,0.761,0.862,0.452,D,c,-0.272,-0.097,1,0.467,0.65,0.456,0,4.06,0.464,1.723,0.374,1.083,0.853,0.917,0.316,1,0.888,3.255,0.064,.,.,.,,,,,,,,,,,,,,,,,,,,,chr2,60688440,.,A,C,.,PASS,ADP=132;WT=0;HET=1;HOM=0;NC=0,GT:GQ:SDP:DP:RD:AD:FREQ:PVAL:RBQ:ABQ:RDF:RDR:ADF:ADR:FA,0/1:24:140:132:124:8:6.06%:3.5022E-3:35:21:96:28:4:4:0.0606
4,chr2,141359040,141359040,A,G,LRP1B,NM_018557,c.6968T>C,p.Leu2323Pro,300,0.4767,IGV,,,,'2/293',,True,,,255,Exonic;VAF>=0.05;DP>=100,VarScan2,'2/293',0.4767;0.4801;0.4801;0.4835,SE21-1318_AMDL2021_Hi5-01_Hi5_AGXTHSv2;SE20-0964_VEN-264-ARC-1_Hi5_AGXTHSv2,'1/12',0.4767;0.4767;0.4767;0.4767,,,LRP1B;NM_018557.2;exon_42,exon42,exonic,,,,http://205.210.128.135:8000/gene/LRP1B/variant/p.Leu2323Pro/result#report,"Gene Role: Tumor suppressor (PMID: 30606230);Highest Evidence Level: C;Highest Tier: II;LRP1B, LDL receptor related protein 1B, is a  tumor repressor (PMID: 20095042) and a cell surface receptor (PMID: 11384978) that may negatively regulate urokinase plasminogen activator receptor regeneration and cell migration (PMID: 12194987). Mutations in LRP1B are frequently observed in melanoma, lung cancer, esophageal squamous-cell carcinoma, head and neck squamous cancer, and gastric cancer (PMID: 31164891) and may be associated with high tumor mutational burden (PMID: 31164891, PMID: 31493933).",,LRP1B,,nonsynonymous SNV,LRP1B:NM_018557:exon42:c.T6968C:p.L2323P,exonic,LRP1B,,nonsynonymous SNV,LRP1B:NM_018557:exon42:c.T6968C:p.L2323P,exonic,LRP1B,,nonsynonymous SNV,LRP1B:uc002tvj.1:exon42:c.T6968C:p.L2323P,,,,,,,,,,,,,,,,,,,0.01,,,,,,,,,0.989,D,0.768,P,0.794,5.893,27.4,0.999,1.062,0.984,0.008,0.586,D,0,0.629,D,1,0.506,D,2.33,0.67,M,-3.09,0.926,D,-4.58,0.788,D,0.786,0.942,D,0.808,0.935,D,0.208,0.872,D,0.734,0.867,0.958,0.658,D,c,0.701,0.689,1,0.747,0.487,0.133,0,5.24,0.728,9.189,0.94,1.088,0.866,0.992,0.373,0.984,0.507,15.422,0.746,"Six-bladed beta-propeller, TolB-like",.,.,,,,,,,,,,,,,,,,,,,,,chr2,141359040,.,A,G,.,PASS,ADP=300;WT=0;HET=1;HOM=0;NC=0,GT:GQ:SDP:DP:RD:AD:FREQ:PVAL:RBQ:ABQ:RDF:RDR:ADF:ADR:FA,0/1:255:300:300:157:143:47.67%:1.4206E-53:58:64:135:22:113:30:0.4767
5,chr3,47163011,47163011,A,G,SETD2,NM_014159,c.3115T>C,p.Ser1039Pro,638,0.4608,IGV,,,,'2/293',,True,,,255,Exonic;VAF>=0.05;DP>=100,VarScan2,'2/293',0.4608;0.4674;0.4674;0.474,SE21-1318_AMDL2021_Hi5-01_Hi5_AGXTHSv2;SE20-0964_VEN-264-ARC-1_Hi5_AGXTHSv2,'1/12',0.4608;0.4608;0.4608;0.4608,,,SETD2;NM_014159.6;exon_3,exon3,exonic,,,,http://205.210.128.135:8000/gene/SETD2/variant/p.Ser1039Pro/result#report,"Gene Role: Tumor suppressor (PMID: 30606230);Highest Evidence Level: D;Highest Tier: II;SETD2, histone-lysine N-methyltransferase SETD2, regulates chromatin structure through H3K36 to influence gene transcription (PMID: 28159833; PMID: 28386724) and plays a role in genomic stability (PMID: 31747945). Loss of function and decreased expression of Setd2 has been demonstrated in clear cell renal cell carcinoma (PMID: 28260718), breast cancer (PMID: 20501857) and lung cancer (PMID: 28202515).",,SETD2,,nonsynonymous SNV,SETD2:NM_014159:exon3:c.T3115C:p.S1039P,exonic,SETD2,,nonsynonymous SNV,SETD2:NM_014159:exon3:c.T3115C:p.S1039P,exonic,SETD2,,nonsynonymous SNV,SETD2:uc003cqs.3:exon3:c.T3115C:p.S1039P;SETD2:uc003cqv.3:exon3:c.T3082C:p.S1028P,,,,,,,,,,,,,,,,,,,0,,,,,,,rs752515394,,0.355,B,0.057,B,0.602,5.056,25.2,0.999,1.062,0.983,0,0.912,D,0,0.559,D,0.954,0.378,D,1.1,0.281,L,-2.78,0.91,D,-1.46,0.644,N,0.12,0.845,D,0.53,0.826,D,0.081,0.738,D,0.208,0.125,0.97,0.719,D,c,0.069,0.226,1,0.747,0.732,0.924,0,5.03,0.669,5.226,0.649,1.199,0.96,1,0.715,1,0.888,14.94,0.705,.,.,.,,,,,,,,,,,,,1.649e-05,0,0,0,0,0,0,0.0001,chr3,47163011,.,A,G,.,PASS,ADP=638;WT=0;HET=1;HOM=0;NC=0,GT:GQ:SDP:DP:RD:AD:FREQ:PVAL:RBQ:ABQ:RDF:RDR:ADF:ADR:FA,0/1:255:640:638:343:294:46.08%:1.3306E-108:60:60:258:85:228:66:0.4608
6,chr4,154624666,154624666,C,A,TLR2,NM_003264,c.607C>A,p.Leu203Met,388,0.8505,IGV,,,,'2/293',,True,,,255,Exonic;VAF>=0.05;DP>=100,VarScan2,'2/293',0.8505;0.8574;0.8574;0.8642,SE21-1318_AMDL2021_Hi5-01_Hi5_AGXTHSv2;SE20-0964_VEN-264-ARC-1_Hi5_AGXTHSv2,'1/12',0.8505;0.8505;0.8505;0.8505,,,TLR2;NM_003264.4;exon_3,exon3,exonic,,,,http://205.210.128.135:8000/gene/TLR2/variant/p.Leu203Met/result#report,,,TLR2,,nonsynonymous SNV,TLR2:NM_003264:exon3:c.C607A:p.L203M,exonic,TLR2,,nonsynonymous SNV,TLR2:NM_003264:exon3:c.C607A:p.L203M,exonic,TLR2,,nonsynonymous SNV,TLR2:uc021xtl.1:exon1:c.C607A:p.L203M;TLR2:uc003ins.3:exon2:c.C607A:p.L203M;TLR2:uc003inq.3:exon3:c.C607A:p.L203M;TLR2:uc003inr.3:exon3:c.C607A:p.L203M,,,,,,,,,,,,,,,,,,,0.23,,,,,,,,,0.933,P,0.817,P,0.682,2.358,18.54,0.988,0.033,0.005,0.329,0.132,T,0.001,0.429,D,1,0.09,N,1.855,0.493,L,-4.66,0.98,D,-0.64,0.187,N,0.452,0.899,D,0.882,0.961,D,0.183,0.857,D,0.576,0.701,0.117,0.166,N,c,-0.137,-0.26,0.998,0.358,0.554,0.283,0,3.76,0.422,-0.016,0.124,0.935,0.49,0.004,0.165,0.022,0.137,4.583,0.116,"Leucine-rich repeat domain, L domain-like",.,.,,,,,,,,,,,,,,,,,,,,,chr4,154624666,.,C,A,.,PASS,ADP=388;WT=0;HET=0;HOM=1;NC=0,GT:GQ:SDP:DP:RD:AD:FREQ:PVAL:RBQ:ABQ:RDF:RDR:ADF:ADR:FA,1/1:255:388:388:58:330:85.05%:3.5521E-159:65:53:41:17:257:73:0.8505
7,chr6,33287188,33287188,T,G,DAXX,NM_001141970,c.1945A>C,p.Lys649Gln,357,0.619,IGV,,,,'4/293',,True,,,255,Exonic;VAF>=0.05;DP>=100,VarScan2,'4/293',0.4439;0.537;0.5342;0.619,SE21-1318_AMDL2021_Hi5-01_Hi5_AGXTHSv2;SE20-0964_VEN-264-ARC-1_Hi5_AGXTHSv2;SE20-2393_NEC-046_Hi5_AGXTHSv2;SE20-2525_VEN-309-ARC-1_Hi5_AGXTHSv2,'1/12',0.619;0.619;0.619;0.619,,,DAXX;NM_001141970.1;exon_6,exon6,exonic,,,,http://205.210.128.135:8000/gene/DAXX/variant/p.Lys649Gln/result#report,"Gene Role: Both: Oncogene and Tumor suppressor (PMID: 30606230);Highest Evidence Level: NA;Highest Tier: NA;DAXX, death domain associated protein, is a transcriptional co-regulator that represses activity of transcriptional factors including C/EBPB, c-Met, Pax3, Ets1, p53, AR, and SMAD4 (PMID: 23539629, PMID: 31350900). Loss of Daxx expression has been linked to ovarian cancer and pancreatic neuroendocrine tumors, while overexpression has been observed in oral squamous cell carcinoma and prostate cancer (PMID: 26205068, PMID: 27162024, PMID: 23954140, PMID: 23642739), and DAXX mutations have been observed in pancreatic neuroendocrine tumors (PMID: 31819132).",,DAXX,,nonsynonymous SNV,DAXX:NM_001141970:exon6:c.A1945C:p.K649Q,exonic,DAXX,,nonsynonymous SNV,DAXX:NM_001254717:exon5:c.A1684C:p.K562Q;DAXX:NM_001141969:exon6:c.A1909C:p.K637Q;DAXX:NM_001141970:exon6:c.A1945C:p.K649Q;DAXX:NM_001350:exon6:c.A1909C:p.K637Q,exonic,DAXX,,nonsynonymous SNV,DAXX:uc011drd.2:exon5:c.A1684C:p.K562Q;DAXX:uc021ywn.1:exon5:c.A1909C:p.K637Q;DAXX:uc021ywo.1:exon5:c.A1909C:p.K637Q;DAXX:uc003oec.3:exon6:c.A1909C:p.K637Q;DAXX:uc003oed.3:exon6:c.A1909C:p.K637Q;DAXX:uc011dre.2:exon6:c.A1945C:p.K649Q,,,,,,,,,,,,,,,,,,,0.15,,,,,,,rs200527264,rs200527264,0,B,0.003,B,0.075,-2.392,0.001,0.406,0.046,0.417,0.157,0.243,T,0.187,0.169,N,1,0.09,N,1.345,0.336,L,.,.,.,-0.44,0.172,N,-1.032,0.198,T,0.021,0.088,T,0.009,0.249,T,0.441,0.497,0.013,0.044,N,c,-1.644,-1.782,1,0.747,0.722,0.854,0,-4.21,0.035,-0.521,0.063,-0.799,0.032,0.001,0.137,0.598,0.288,2.584,0.045,.,.,.,,,,,,0.000199681,,0.0014,,,,,3.3e-05,0,8.637e-05,0,0,4.503e-05,0,0,chr6,33287188,.,T,G,.,PASS,ADP=357;WT=0;HET=1;HOM=0;NC=0,GT:GQ:SDP:DP:RD:AD:FREQ:PVAL:RBQ:ABQ:RDF:RDR:ADF:ADR:FA,0/1:255:361:357:136:221:61.9%:2.0103E-89:56:62:100:36:170:51:0.6190
8,chr6,51618101,51618101,C,T,PKHD1,NM_138694,c.8848G>A,p.Val2950Ile,323,0.5139,IGV,,,,'2/293',,True,,,255,Exonic;VAF>=0.05;DP>=100,VarScan2,'2/293',0.4679;0.4909;0.4909;0.5139,SE21-1318_AMDL2021_Hi5-01_Hi5_AGXTHSv2;SE20-0964_VEN-264-ARC-1_Hi5_AGXTHSv2,'1/12',0.5139;0.5139;0.5139;0.5139,,,PKHD1;NM_138694.3;exon_57,exon57,exonic,,,,http://205.210.128.135:8000/gene/PKHD1/variant/p.Val2950Ile/result#report,,,PKHD1,,nonsynonymous SNV,PKHD1:NM_138694:exon57:c.G8848A:p.V2950I,exonic,PKHD1,,nonsynonymous SNV,PKHD1:NM_138694:exon57:c.G8848A:p.V2950I;PKHD1:NM_170724:exon57:c.G8848A:p.V2950I,exonic,PKHD1,,nonsynonymous SNV,PKHD1:uc010jzn.1:exon21:c.G2797A:p.V933I;PKHD1:uc003pah.1:exon57:c.G8848A:p.V2950I;PKHD1:uc003pai.3:exon57:c.G8848A:p.V2950I,,3.185e-05,6.483e-05,5.726e-05,0,3.183e-05,0,.,0,0,6.483e-05,0,0,0,9.022e-05,7.344e-05,.,.,0.06,,,,,,,rs768138709,,1,D,0.994,D,0.585,6.314,29.2,0.999,0.871,0.994,0,0.912,D,0,0.629,D,0.895,0.36,D,3.08,0.875,M,-1.94,0.849,D,-0.84,0.229,N,0.658,0.927,D,0.756,0.917,D,0.121,0.803,D,0.51,0.607,0.879,0.473,D,c,0.762,0.722,0.986,0.309,0.554,0.283,0,5.75,0.904,2.755,0.47,0.935,0.49,1,0.715,0.989,0.536,18.941,0.925,.,.,.,,,,,,,,,,,,,8.246e-05,0,0,0,0,2.998e-05,0,0.0005,chr6,51618101,.,C,T,.,PASS,ADP=323;WT=0;HET=1;HOM=0;NC=0,GT:GQ:SDP:DP:RD:AD:FREQ:PVAL:RBQ:ABQ:RDF:RDR:ADF:ADR:FA,0/1:255:325:323:157:166:51.39%:2.4764E-63:64:61:110:47:122:44:0.5139
9,chr6,152163775,152163775,G,A,ESR1,NM_000125,c.496G>A,p.Ala166Thr,364,0.3297,IGV,,,,'2/293',,True,,,255,Exonic;VAF>=0.05;DP>=100,VarScan2,'2/293',0.3297;0.3406;0.3406;0.3514,SE21-1318_AMDL2021_Hi5-01_Hi5_AGXTHSv2;SE20-0964_VEN-264-ARC-1_Hi5_AGXTHSv2,'1/12',0.3297;0.3297;0.3297;0.3297,,,ESR1;NM_000125.3;exon_2,exon2,exonic,,,,http://205.210.128.135:8000/gene/ESR1/variant/p.Ala166Thr/result#report,"Gene Role: Both: Oncogene and Tumor suppressor (PMID: 30606230);Highest Evidence Level: A;Highest Tier: I;ESR1, estrogen receptor alpha, modulates response to estrogen and is used as a marker to predict response to endocrine therapy in breast cancer patients (PMID: 23542176, PMID: 26183887). ESR1 fusions are recurrent in breast cancer, and mutations in ESR1 have been associated with decreased response to endocrine therapy (PMID: 27372070, PMID: 26183887) in breast cancer (PMID: 31795152).",,ESR1,,nonsynonymous SNV,ESR1:NM_000125:exon2:c.G496A:p.A166T,exonic,ESR1,,nonsynonymous SNV,ESR1:NM_000125:exon2:c.G496A:p.A166T;ESR1:NM_001122740:exon3:c.G496A:p.A166T;ESR1:NM_001122741:exon3:c.G496A:p.A166T;ESR1:NM_001291230:exon3:c.G496A:p.A166T;ESR1:NM_001291241:exon3:c.G496A:p.A166T;ESR1:NM_001122742:exon4:c.G496A:p.A166T,exonic,ESR1,,nonsynonymous SNV,ESR1:uc003qoo.4:exon2:c.G496A:p.A166T;ESR1:uc003qon.4:exon3:c.G496A:p.A166T;ESR1:uc010kin.3:exon3:c.G496A:p.A166T;ESR1:uc010kio.3:exon3:c.G496A:p.A166T;ESR1:uc010kip.3:exon3:c.G496A:p.A166T;ESR1:uc031sqc.1:exon3:c.G496A:p.A166T;ESR1:uc003qom.4:exon4:c.G496A:p.A166T;ESR1:uc031sqb.1:exon4:c.G496A:p.A166T;ESR1:uc021zgx.1:exon5:c.G496A:p.A166T;ESR1:uc031sqa.1:exon5:c.G496A:p.A166T,,,,,,,,,,,,,,,,,,,0.18,,,,,,,,,0.001,B,0.026,B,0.184,1.331,12.43,0.967,-0.02,0.962,0.338,0.128,T,0.003,0.356,N,1,0.81,D,1.385,0.346,L,1.5,0.312,T,-0.34,0.127,N,-1.076,0.081,T,0.07,0.284,T,0.008,0.209,T,0.304,0.274,0.801,0.395,D,c,-0.151,-0.079,0.001,0.085,0.487,0.133,0,3.24,0.361,0.543,0.228,-0.354,0.069,1,0.715,0.929,0.403,6.315,0.203,.,.,.,,,,,,,,,,,,,,,,,,,,,chr6,152163775,.,G,A,.,PASS,ADP=364;WT=0;HET=1;HOM=0;NC=0,GT:GQ:SDP:DP:RD:AD:FREQ:PVAL:RBQ:ABQ:RDF:RDR:ADF:ADR:FA,0/1:255:370:364:244:120:32.97%:5.5875E-42:61:53:214:30:100:20:0.3297
10,chr7,126883190,126883190,C,A,GRM8,NM_000845,c.69G>T,p.Trp23Cys,278,0.2914,IGV,,,,'2/293',,True,,,255,Exonic;VAF>=0.05;DP>=100,VarScan2,'2/293',0.2914;0.3064;0.3064;0.3214,SE21-1318_AMDL2021_Hi5-01_Hi5_AGXTHSv2;SE20-0964_VEN-264-ARC-1_Hi5_AGXTHSv2,'1/12',0.2914;0.2914;0.2914;0.2914,,,GRM8;NM_000845.2;exon_1,exon1,exonic,,,,http://205.210.128.135:8000/gene/GRM8/variant/p.Trp23Cys/result#report,,,GRM8,,nonsynonymous SNV,GRM8:NM_000845:exon1:c.G69T:p.W23C,exonic,GRM8,,nonsynonymous SNV,GRM8:NM_000845:exon1:c.G69T:p.W23C;GRM8:NM_001127323:exon2:c.G69T:p.W23C,exonic,GRM8,,nonsynonymous SNV,GRM8:uc003vlr.2:exon1:c.G69T:p.W23C;GRM8:uc003vlt.2:exon2:c.G69T:p.W23C,,,,,,,,,,,,,,,,,,,0,,,,,,,,,0.785,P,0.321,B,0.835,3.919,23.5,0.953,0.871,1,0.005,0.721,D,0.002,0.384,N,1,0.81,D,2.32,0.666,M,-0.34,0.685,T,-1.7,0.433,N,-0.738,0.586,T,0.227,0.592,T,0.012,0.301,T,0.677,0.815,0.972,0.733,D,c,0.317,0.44,0.63,0.22,0.615,0.372,0,6.17,0.997,3.718,0.544,0.935,0.49,1,0.715,1,0.888,13.08,0.583,.,.,.,,,,,,,,,,,,,,,,,,,,,chr7,126883190,.,C,A,.,PASS,ADP=278;WT=0;HET=1;HOM=0;NC=0,GT:GQ:SDP:DP:RD:AD:FREQ:PVAL:RBQ:ABQ:RDF:RDR:ADF:ADR:FA,0/1:255:278:278:197:81:29.14%:4.3959E-28:62:51:134:63:54:27:0.2914
11,chr7,138258307,138258307,T,C,TRIM24,NM_015905,c.1934T>C,p.Ile645Thr,577,0.184,IGV,,,,'2/293',,True,,,255,Exonic;VAF>=0.05;DP>=100,VarScan2,'2/293',0.184;0.198;0.198;0.2119,SE21-1318_AMDL2021_Hi5-01_Hi5_AGXTHSv2;SE20-0964_VEN-264-ARC-1_Hi5_AGXTHSv2,'1/12',0.184;0.184;0.184;0.184,,,TRIM24;NM_015905.2;exon_12,exon12,exonic,,"Benign (5/7): MutationAssessor, LRT, Polyphen2_HDIV, Polyphen2_HVAR, PROVEAN",,http://205.210.128.135:8000/gene/TRIM24/variant/p.Ile645Thr/result#report,"Gene Role: Both: Oncogene and Tumor suppressor (PMID: 30606230);Highest Evidence Level: D;Highest Tier: II;TRIM24, tripartite motif containing 24, functions as E3 ubiquitin ligase that regulates Tp53 degradation, and also acts to regulate the transactivation activity of multiple nuclear receptors (PMID: 21979307, PMID: 19844164). TRIM24 fusions, with multiple fusion partners, have been identified in several cancer types, including  including liver, thyroid (PMID: 24409330, PMID: 21979307), lung adenocarcinoma (PMID: 25204415), and melanoma (PMID: 24345920, PMID: 30254212), and Trim24 overexpression has been associated with more aggressive prostate cancer (PMID: 31178279).",,TRIM24,,nonsynonymous SNV,TRIM24:NM_015905:exon12:c.T1934C:p.I645T,exonic,TRIM24,,nonsynonymous SNV,TRIM24:NM_003852:exon12:c.T1832C:p.I611T;TRIM24:NM_015905:exon12:c.T1934C:p.I645T,exonic,TRIM24,,nonsynonymous SNV,TRIM24:uc003vub.3:exon12:c.T1832C:p.I611T;TRIM24:uc003vuc.3:exon12:c.T1934C:p.I645T,,,,,,,,,,,,,,,,,,,0.06,,,,,,,,,0.01,B,0.006,B,0.097,-0.189,1.158,0.637,0.991,0.98,0.085,0.334,T,0.288,0.148,N,1,0.09,N,0.69,0.17,N,-0.94,0.753,T,0.19,0.05,N,-1,0.301,T,0.162,0.498,T,0.014,0.337,T,0.161,0.065,0.05,0.107,N,c,-1.184,-1.115,0.109,0.166,0.732,0.924,0,-0.819,0.102,0.197,0.169,0.004,0.136,0,0.063,0.977,0.48,11.436,0.491,.,.,.,,,,,,,,,,,,,,,,,,,,,chr7,138258307,.,T,C,.,PASS,ADP=577;WT=0;HET=1;HOM=0;NC=0,GT:GQ:SDP:DP:RD:AD:FREQ:PVAL:RBQ:ABQ:RDF:RDR:ADF:ADR:FA,0/1:255:577:577:470:106:18.4%:5.9901E-35:58:65:363:107:87:19:0.1840
12,chr9,8521505,8521505,G,T,PTPRD,NM_002839,c.733C>A,p.His245Asn,367,0.4169,IGV,,,,'2/293',,True,,,255,Exonic;VAF>=0.05;DP>=100,VarScan2,'2/293',0.4169;0.4195;0.4195;0.4221,SE21-1318_AMDL2021_Hi5-01_Hi5_AGXTHSv2;SE20-0964_VEN-264-ARC-1_Hi5_AGXTHSv2,'1/12',0.4169;0.4169;0.4169;0.4169,,,PTPRD;NM_002839.3;exon_20,exon20,exonic,,,,http://205.210.128.135:8000/gene/PTPRD/variant/p.His245Asn/result#report,"Gene Role: Tumor suppressor (PMID: 30606230);Highest Evidence Level: D;Highest Tier: II;PTPRD, protein tyrosine phosphatase receptor type D, is a transmembrane protein (PMID: 30208623) that plays a role in cell growth, adhesion, migration, survival (PMID: 25113440), and regulates neurodevelopment (PMID: 31914388). PTPRD is inactivated in a variety of solid tumors (PMID: 19478061), including advanced stage gastric cancer (PMID: 31805999, PMID: 31041642), laryngeal squamous cell carcinoma (PMID: 28345455), and copy number alterations have been reported in Ewing's sarcoma (PMID: 31072725).",,PTPRD,,nonsynonymous SNV,PTPRD:NM_002839:exon20:c.C733A:p.H245N,exonic,PTPRD,,nonsynonymous SNV,PTPRD:NM_001171025:exon7:c.C703A:p.H235N;PTPRD:NM_001040712:exon8:c.C724A:p.H242N;PTPRD:NM_130393:exon8:c.C715A:p.H239N;PTPRD:NM_130391:exon9:c.C733A:p.H245N;PTPRD:NM_130392:exon9:c.C733A:p.H245N;PTPRD:NM_002839:exon20:c.C733A:p.H245N,exonic,PTPRD,,nonsynonymous SNV,PTPRD:uc003zks.3:exon7:c.C703A:p.H235N;PTPRD:uc003zkr.3:exon8:c.C715A:p.H239N;PTPRD:uc022bdj.1:exon8:c.C724A:p.H242N;PTPRD:uc003zkp.3:exon9:c.C733A:p.H245N;PTPRD:uc003zkq.3:exon9:c.C733A:p.H245N;PTPRD:uc003zkk.3:exon20:c.C733A:p.H245N,,,,,,,,,,,,,,,,,,,0.02,,,,,,,,,0.017,B,0.011,B,0.165,4.482,24.2,0.982,0.917,1,0.092,0.486,T,0,0.843,D,1,0.524,D,2.045,0.562,M,-0.22,0.665,T,-3.44,0.674,D,-0.824,0.537,T,0.235,0.602,T,0.01,0.26,T,0.384,0.404,0.936,0.583,D,c,0.12,0.322,1,0.747,0.638,0.428,0,5.68,0.88,7.531,0.807,1.048,0.713,1,0.715,1,0.888,19.792,0.964,Immunoglobulin subtype|Immunoglobulin-like domain|Immunoglobulin-like fold;Immunoglobulin-like domain|Immunoglobulin-like fold,.,.,,,,,,,,,,,,,,,,,,,,,chr9,8521505,.,G,T,.,PASS,ADP=367;WT=0;HET=1;HOM=0;NC=0,GT:GQ:SDP:DP:RD:AD:FREQ:PVAL:RBQ:ABQ:RDF:RDR:ADF:ADR:FA,0/1:255:367:367:213:153:41.69%:1.3322E-55:64:51:152:61:86:67:0.4169
13,chr13,73351596,73351596,C,T,DIS3,NM_014953,c.616G>A,p.Glu206Lys,278,0.7842,IGV,,,,'2/293',,True,,,255,Exonic;VAF>=0.05;DP>=100,VarScan2,'2/293',0.7838;0.784;0.784;0.7842,SE21-1318_AMDL2021_Hi5-01_Hi5_AGXTHSv2;SE20-0964_VEN-264-ARC-1_Hi5_AGXTHSv2,'1/12',0.7842;0.7842;0.7842;0.7842,,,DIS3;NM_014953.4;exon_4,exon4,exonic,,,,http://205.210.128.135:8000/gene/DIS3/variant/p.Glu206Lys/result#report,,,DIS3,,nonsynonymous SNV,DIS3:NM_014953:exon4:c.G616A:p.E206K,exonic,DIS3,,nonsynonymous SNV,DIS3:NM_001128226:exon4:c.G526A:p.E176K;DIS3:NM_014953:exon4:c.G616A:p.E206K,exonic,DIS3,,nonsynonymous SNV,DIS3:uc001vix.4:exon4:c.G616A:p.E206K;DIS3:uc001viy.4:exon4:c.G526A:p.E176K,,6.375e-05,0.0001,5.725e-05,7.191e-05,6.366e-05,0.0001,.,0,0,6.486e-05,0,0,0,0.0001,0.0003,.,.,0.74,ID=COSM1477299;OCCURENCE=1(breast),,,,,,rs760670933,,0.873,P,0.287,B,0.659,4.031,23.7,0.997,0.871,0.998,0.489,0.097,T,0,0.843,D,1,0.81,D,2.255,0.644,M,1.86,0.243,T,-2.02,0.465,N,-1.059,0.12,T,0.081,0.32,T,0.015,0.358,T,.,.,0.992,0.926,D,c,0.46,0.533,1,0.747,0.707,0.73,0,5.46,0.799,6.915,0.754,0.892,0.403,1,0.715,0.993,0.574,19.659,0.958,PIN domain|PIN domain-like,.,.,,,,,,,,,,,,,2.491e-05,9.686e-05,0,0.0001,0,0,0,6.094e-05,chr13,73351596,.,C,T,.,PASS,ADP=278;WT=0;HET=0;HOM=1;NC=0,GT:GQ:SDP:DP:RD:AD:FREQ:PVAL:RBQ:ABQ:RDF:RDR:ADF:ADR:FA,1/1:255:279:278:60:218:78.42%:3.1051E-99:64:62:53:7:173:45:0.7842
14,chr13,110435373,110435373,C,T,IRS2,NM_003749,c.3028G>A,p.Ala1010Thr,343,0.4869,IGV,,,,'2/293',,True,,,255,Exonic;VAF>=0.05;DP>=100,VarScan2,'2/293',0.435;0.461;0.461;0.4869,SE21-1318_AMDL2021_Hi5-01_Hi5_AGXTHSv2;SE20-0964_VEN-264-ARC-1_Hi5_AGXTHSv2,'1/12',0.4869;0.4869;0.4869;0.4869,,,IRS2;NM_003749.2;exon_1,exon1,exonic,,,,http://205.210.128.135:8000/gene/IRS2/variant/p.Ala1010Thr/result#report,"Gene Role: Unknown;Highest Evidence Level: C;Highest Tier: II;IRS2, insulin receptor substrate 2, is a member of the IRS family of intracellular adaptor proteins, which is involved in mediating IGF-IR signaling and functions in regulation of growth, metabolism (PMID: 17030631, PMID: 25200290), glucose uptake, cell migration, and cell invasion (PMID: 29669935). Overexpression and amplification of IRS2 are associated with colorectal cancer, breast cancer (PMID: 23594372, PMID: 23562473), and intrahepatic cholangiocarcinoma (PMID: 30250623) and gain of function mutations have been reported in pleomorphic invasive lobular breast carcinoma (PMID: 29669935).",,IRS2,,nonsynonymous SNV,IRS2:NM_003749:exon1:c.G3028A:p.A1010T,exonic,IRS2,,nonsynonymous SNV,IRS2:NM_003749:exon1:c.G3028A:p.A1010T,exonic,IRS2,,nonsynonymous SNV,IRS2:uc001vqv.3:exon1:c.G3028A:p.A1010T,,3.23e-05,.,0,7.282e-05,3.183e-05,0,.,0,0,0,0,0,0.0009,.,.,.,.,0.19,,,,,,,,,0.675,P,0.133,B,0.12,1.186,11.67,0.99,0.853,0.711,0.338,0.128,T,0.356,0.137,U,0.932,0.27,N,2.08,0.576,M,0.71,0.512,T,-0.76,0.212,N,-1.05,0.144,T,0.09,0.345,T,0.133,0.816,D,0.204,0.12,0.993,0.946,D,c,-0.21,-0.226,1,0.747,0.696,0.567,0,4.18,0.483,1.935,0.396,0.778,0.314,0.834,0.299,0.079,0.18,9.653,0.389,.,.,.,,,,,,,,,,,,,0,0,0,0,0,0,0,0,chr13,110435373,.,C,T,.,PASS,ADP=343;WT=0;HET=1;HOM=0;NC=0,GT:GQ:SDP:DP:RD:AD:FREQ:PVAL:RBQ:ABQ:RDF:RDR:ADF:ADR:FA,0/1:255:350:343:176:167:48.69%:8.5782E-63:60:39:161:15:147:20:0.4869
15,chr14,99640538,99640538,C,T,BCL11B,NM_138576,c.2635G>A,p.Glu879Lys,592,0.3868,IGV,,,,'2/293',,True,,,255,Exonic;VAF>=0.05;DP>=100,VarScan2,'2/293',0.3868;0.3959;0.3959;0.405,SE21-1318_AMDL2021_Hi5-01_Hi5_AGXTHSv2;SE20-0964_VEN-264-ARC-1_Hi5_AGXTHSv2,'1/12',0.3868;0.3868;0.3868;0.3868,,,BCL11B;NM_138576.3;exon_4,exon4,exonic,,,,http://205.210.128.135:8000/gene/BCL11B/variant/p.Glu879Lys/result#report,,,BCL11B,,nonsynonymous SNV,BCL11B:NM_138576:exon4:c.G2635A:p.E879K,exonic,BCL11B,,nonsynonymous SNV,BCL11B:NM_001282238:exon3:c.G2419A:p.E807K;BCL11B:NM_022898:exon3:c.G2422A:p.E808K;BCL11B:NM_001282237:exon4:c.G2632A:p.E878K;BCL11B:NM_138576:exon4:c.G2635A:p.E879K,exonic,BCL11B,,nonsynonymous SNV,BCL11B:uc001ygb.3:exon3:c.G2422A:p.E808K;BCL11B:uc031qqi.1:exon3:c.G2419A:p.E807K;BCL11B:uc001yga.3:exon4:c.G2635A:p.E879K;BCL11B:uc031qqh.1:exon4:c.G2632A:p.E878K,,,,,,,,,,,,,,,,,,,0.01,,,,,,,,,0.998,D,0.866,P,0.667,5.423,26,0.999,0.871,0.992,0.047,0.419,D,0.037,0.244,N,1,0.588,D,1.77,0.46,L,2.12,0.197,T,-1.82,0.446,N,-1.003,0.29,T,0.11,0.397,T,0.018,0.404,T,0.541,0.653,0.982,0.808,D,c,0.521,0.532,1,0.747,0.701,0.575,0,4.87,0.627,5.861,0.691,0.826,0.337,1,0.715,0.997,0.653,17.989,0.89,Zinc finger C2H2-type,.,.,,,,,,,,,,,,,,,,,,,,,chr14,99640538,.,C,T,.,PASS,ADP=592;WT=0;HET=1;HOM=0;NC=0,GT:GQ:SDP:DP:RD:AD:FREQ:PVAL:RBQ:ABQ:RDF:RDR:ADF:ADR:FA,0/1:255:593:592:363:229:38.68%:1.2096E-81:59:60:288:75:194:35:0.3868
16,chr15,91341457,91341457,G,A,BLM,NM_000057,c.3248G>A,p.Ser1083Asn,129,0.8372,IGV,,,,'2/293',,True,,,255,Exonic;VAF>=0.05;DP>=100,VarScan2,'2/293',0.743;0.7901;0.7901;0.8372,SE21-1318_AMDL2021_Hi5-01_Hi5_AGXTHSv2;SE20-0964_VEN-264-ARC-1_Hi5_AGXTHSv2,'1/12',0.8372;0.8372;0.8372;0.8372,,,BLM;NM_000057.3;exon_17,exon17,exonic,,"Benign (5/7): MutationAssessor, LRT, Polyphen2_HDIV, Polyphen2_HVAR, PROVEAN",,http://205.210.128.135:8000/gene/BLM/variant/p.Ser1083Asn/result#report,"Gene Role: Tumor suppressor (PMID: 30606230);Highest Evidence Level: D;Highest Tier: II;BLM, BLM RecQ like helicase, is a DNA helicase that plays important roles in maintaining genomic integrity (PMID: 28232778, PMID: 29278995). Loss of Blm protein function leads to Bloom's syndrome and increased cancer risk (PMID: 28232778, PMID: 28647934).",,BLM,,nonsynonymous SNV,BLM:NM_000057:exon17:c.G3248A:p.S1083N,exonic,BLM,,nonsynonymous SNV,BLM:NM_000057:exon17:c.G3248A:p.S1083N;BLM:NM_001287247:exon17:c.G3248A:p.S1083N;BLM:NM_001287248:exon17:c.G2123A:p.S708N;BLM:NM_001287246:exon18:c.G3248A:p.S1083N,exonic,BLM,,nonsynonymous SNV,BLM:uc002bpr.3:exon17:c.G3248A:p.S1083N;BLM:uc010bnx.3:exon17:c.G3248A:p.S1083N;BLM:uc010uqi.2:exon17:c.G2123A:p.S708N;BLM:uc010uqh.2:exon18:c.G3248A:p.S1083N,,,,,,,,,,,,,,,,,,,0.93,,,,,,,rs775134111,,0.001,B,0.004,B,0.009,0.492,7.368,0.192,0.045,0.994,1,0.01,T,0,0.513,N,0.736,0.298,N,-0.49,0.026,N,1,0.414,T,0.36,0.037,N,-1.036,0.184,T,0.034,0.148,T,0.005,0.119,T,0.341,0.334,0.148,0.184,N,c,-0.771,-0.525,0.999,0.375,0.732,0.924,0,3.38,0.376,2.566,0.454,-0.262,0.088,1,0.715,0.924,0.398,8.821,0.34,P-loop containing nucleoside triphosphate hydrolase|RQC domain|Winged helix-turn-helix DNA-binding domain;P-loop containing nucleoside triphosphate hydrolase|Winged helix-turn-helix DNA-binding domain,.,.,,,,,,,,,,,,,,,,,,,,,chr15,91341457,.,G,A,.,PASS,ADP=129;WT=0;HET=0;HOM=1;NC=0,GT:GQ:SDP:DP:RD:AD:FREQ:PVAL:RBQ:ABQ:RDF:RDR:ADF:ADR:FA,1/1:255:130:129:21:108:83.72%:9.7803E-52:66:56:18:3:101:7:0.8372
17,chr16,50784048,50784048,C,T,CYLD,NM_015247,c.439C>T,p.Arg147Cys,480,0.2542,IGV,,,,'2/293',,True,,,255,Exonic;VAF>=0.05;DP>=100,VarScan2,'2/293',0.2542;0.2642;0.2642;0.2741,SE21-1318_AMDL2021_Hi5-01_Hi5_AGXTHSv2;SE20-0964_VEN-264-ARC-1_Hi5_AGXTHSv2,'1/12',0.2542;0.2542;0.2542;0.2542,,,CYLD;NM_015247.2;exon_4,exon4,exonic,"Damaging (5/7): MutationTaster, LRT, Polyphen2_HDIV, Polyphen2_HVAR, PROVEAN",,,http://205.210.128.135:8000/gene/CYLD/variant/p.Arg147Cys/result#report,"Gene Role: Tumor suppressor (PMID: 30606230);Highest Evidence Level: NA;Highest Tier: NA;CYLD, CYLD lysine 63 deubiquitinase, acts as a tumor suppressor through enzymatic removal of ubiquitin chains on target substrates and its activity influences NFKB, WNT, MAPK, HDAC6, and EGFR pathways among others (PMID: 20347313, PMID: 25342597, PMID: 28572092). Loss of Cyld expression and function is associated with a variety of cancers, including squamous cell carcinomas (PMID: 20347313, PMID: 21900959, PMID: 26982322, PMID: 31635163, PMID: 32892208) and mutations have been reported in nasopharyngeal carcinoma (PMID: 28098136).",,CYLD,,nonsynonymous SNV,CYLD:NM_015247:exon4:c.C439T:p.R147C,exonic,CYLD,,nonsynonymous SNV,CYLD:NM_001042355:exon3:c.C439T:p.R147C;CYLD:NM_001042412:exon3:c.C439T:p.R147C;CYLD:NM_015247:exon4:c.C439T:p.R147C,exonic,CYLD,,nonsynonymous SNV,CYLD:uc002egs.1:exon1:c.C439T:p.R147C;CYLD:uc021tib.1:exon1:c.C439T:p.R147C;CYLD:uc002egn.1:exon3:c.C439T:p.R147C;CYLD:uc002egq.1:exon3:c.C439T:p.R147C;CYLD:uc002egr.1:exon3:c.C439T:p.R147C;CYLD:uc010cbs.1:exon3:c.C439T:p.R147C;CYLD:uc002ego.3:exon4:c.C439T:p.R147C;CYLD:uc002egp.1:exon4:c.C439T:p.R147C,,,,,,,,,,,,,,,,,,,0,ID=COSM3387468;OCCURENCE=1(pancreas),,,,,,,,1,D,0.998,D,0.871,4.213,23.9,0.999,0.871,0.998,0.009,0.912,D,0,0.843,D,1,0.81,D,2.995,0.861,M,-1.67,0.828,D,-7,0.937,D,0.79,0.943,D,0.781,0.925,D,0.204,0.869,D,0.795,0.916,0.949,0.627,D,c,0.78,0.714,1,0.747,0.707,0.73,0,5.21,0.719,3.401,0.521,0.038,0.153,1,0.715,0.946,0.421,15.955,0.796,CAP Gly-rich domain,.,.,,,,,,,,,,,,,,,,,,,,,chr16,50784048,.,C,T,.,PASS,ADP=480;WT=0;HET=1;HOM=0;NC=0,GT:GQ:SDP:DP:RD:AD:FREQ:PVAL:RBQ:ABQ:RDF:RDR:ADF:ADR:FA,0/1:255:481:480:358:122:25.42%:2.7411E-41:60:60:266:92:97:25:0.2542
18,chr16,66434785,66434785,C,T,CDH5,NM_001795,c.1703C>T,p.Thr568Ile,305,0.7934,IGV,,,,'2/293',,True,,,255,Exonic;VAF>=0.05;DP>=100,VarScan2,'2/293',0.7873;0.7904;0.7904;0.7934,SE21-1318_AMDL2021_Hi5-01_Hi5_AGXTHSv2;SE20-0964_VEN-264-ARC-1_Hi5_AGXTHSv2,'1/12',0.7934;0.7934;0.7934;0.7934,,,CDH5;NM_001795.4;exon_11,exon11,exonic,,,,http://205.210.128.135:8000/gene/CDH5/variant/p.Thr568Ile/result#report,,,CDH5,,nonsynonymous SNV,CDH5:NM_001795:exon11:c.C1703T:p.T568I,exonic,CDH5,,nonsynonymous SNV,CDH5:NM_001795:exon11:c.C1703T:p.T568I,exonic,CDH5,,nonsynonymous SNV,CDH5:uc002eom.4:exon11:c.C1703T:p.T568I,,,,,,,,,,,,,,,,,,,0,,,,,,,,,0.977,D,0.896,P,0.634,4.647,24.5,0.995,0.871,0.862,0,0.912,D,.,.,.,0.991,0.412,D,3.11,0.88,M,0.46,0.772,T,-4.82,0.808,D,0.228,0.864,D,0.576,0.847,D,0.122,0.804,D,0.545,0.659,0.912,0.527,D,c,0.261,0.165,1,0.747,0.672,0.522,0,4.11,0.472,6.079,0.707,0.935,0.49,1,0.715,0.607,0.29,12.596,0.556,Cadherin|Cadherin-like,.,.,,,,,,,,,,,,,,,,,,,,,chr16,66434785,.,C,T,.,PASS,ADP=305;WT=0;HET=0;HOM=1;NC=0,GT:GQ:SDP:DP:RD:AD:FREQ:PVAL:RBQ:ABQ:RDF:RDR:ADF:ADR:FA,1/1:255:306:305:63:242:79.34%:5.836E-111:66:54:59:4:196:46:0.7934
19,chr17,40476826,40476826,C,T,STAT3,NM_139276,c.1503G>A,p.Trp501*,323,0.3777,IGV,,,,'2/293',,True,,,255,Exonic;VAF>=0.05;DP>=100,VarScan2,'2/293',0.3777;0.3803;0.3803;0.3829,SE21-1318_AMDL2021_Hi5-01_Hi5_AGXTHSv2;SE20-0964_VEN-264-ARC-1_Hi5_AGXTHSv2,'1/12',0.3777;0.3777;0.3777;0.3777,,,STAT3;NM_139276.2;exon_17,exon17,exonic,,,,http://205.210.128.135:8000/gene/STAT3/variant/p.Trp501*/result#report,"Gene Role: Oncogene (PMID: 30606230);Highest Evidence Level: A;Highest Tier: I;STAT3, signal transducer and activator of transcription 3, is one of seven members of the STAT family of transcription factors that mediates IL6 cytokine signaling and plays a role in inflammation and the anti-tumor response (PMID: 32365499, PMID: 32331320, PMID: 32278856). STAT3 has been shown to demonstrate both oncogenic and tumor suppressor activity, in a context dependent manner, in several solid tumors, including lung, brain, colorectal, pancreatic, thyroid, and prostate cancers (PMID: 32365499) and is often constitutively activated in cancer (PMID: 32278856).",,STAT3,,stopgain,STAT3:NM_139276:exon17:c.G1503A:p.W501X,exonic,STAT3,,stopgain,STAT3:NM_003150:exon17:c.G1503A:p.W501X;STAT3:NM_139276:exon17:c.G1503A:p.W501X;STAT3:NM_213662:exon17:c.G1503A:p.W501X,exonic,STAT3,,stopgain,STAT3:uc010wgh.1:exon16:c.G1209A:p.W403X;STAT3:uc002hzk.1:exon17:c.G1503A:p.W501X;STAT3:uc002hzl.1:exon17:c.G1503A:p.W501X;STAT3:uc002hzm.1:exon17:c.G1503A:p.W501X;STAT3:uc002hzn.1:exon17:c.G1503A:p.W501X,,,,,,,,,,,,,,,,,,,0,,,,,,,,,.,.,.,.,.,13.344,41,0.996,0.871,1,.,.,.,0,0.843,D,1,0.81,A,.,.,.,.,.,.,.,.,.,.,.,.,.,.,.,.,.,.,.,.,0.99,0.899,D,c,0.964,0.849,1,0.983,0.722,0.854,0,5.63,0.861,7.867,0.854,0.935,0.49,1,0.715,0.991,0.552,19.679,0.959,"STAT transcription factor, DNA-binding|p53-like transcription factor, DNA-binding",.,.,,,,,,,,,,,,,,,,,,,,,chr17,40476826,.,C,T,.,PASS,ADP=323;WT=0;HET=1;HOM=0;NC=0,GT:GQ:SDP:DP:RD:AD:FREQ:PVAL:RBQ:ABQ:RDF:RDR:ADF:ADR:FA,0/1:255:323:323:201:122:37.77%:1.2791E-43:64:61:185:16:107:15:0.3777
20,chr19,19256776,19256776,T,G,MEF2B,NM_001145785,c.937A>C,p.Thr313Pro,195,0.0567,IGV,,,,'23/293',,True,,,33,Exonic;VAF>=0.05;DP>=100,VarScan2,'23/293',0.0278;0.0841;0.0839;0.1628,SE20-1635_VEN-286-ARC-1_Hi5_AGXTHSv2;SE20-0964_VEN-264-ARC-1_Hi5_AGXTHSv2;SE21-0611_VEN-347-ARC-1_Hi5_AGXTHSv2;SE20-2529_VEN-268-ARC-1_Hi5_AGXTHSv2;SE20-0963_VEN-263-ARC-1_Hi5_AGXTHSv2;SE21-1293_VEN-329-ARC-1_Hi5_AGXTHSv2;SE21-0334_DIVA-414-BX-1_Hi5_AGXTHSv2;SE20-2389_NEC-035_Hi5_AGXTHSv2;SE21-0091_VEN-332-ARC-1_Hi5_AGXTHSv2;SE21-0812_VEN-131-BX-2_Hi5_AGXTHSv2;SE20-2394_NEC-049_Hi5_AGXTHSv2;SE21-0988_VEN-357-BX-1_Hi5_AGXTHSv2;SE21-0797_VEN-354-ARC-1_Hi5_AGXTHSv2;SE21-0945_VEN-337-ARC-1_Hi5_AGXTHSv2;SE20-0645_DIVA-406-ARC-1_Hi5_AGSSv2;SE21-0060_Seraseq-ctDNA-1-200_Hi5_AGXTHSv2;SE21-0609_DIVA-208-ARC-1_Hi5_AGXTHSv2;SE21-0237_VEN-335-ARC-1_Hi5_AGXTHSv2;SE20-0644_DIVA-169-ARC-1_Hi5_AGSSv2;SE21-0924_DIVA-213-ARC-1_Hi5_AGXTHSv2;SE20-2861_DIVA-197-ARC-1_Hi5_AGXTHSv2;SE21-1318_AMDL2021_Hi5-01_Hi5_AGXTHSv2;SE21-0155_DIVA-201-ARC-1_Hi5_AGXTHSv2,'4/12',0.0567;0.1129;0.1019;0.125,,problematic,MEF2B;NM_001145785.1;exon_9,exon9,exonic,,,,http://205.210.128.135:8000/gene/MEF2B/variant/p.Thr313Pro/result#report,,,MEF2B,,nonsynonymous SNV,MEF2B:NM_001145785:exon9:c.A937C:p.T313P,exonic,MEF2B;MEF2BNB-MEF2B,,nonsynonymous SNV,MEF2B:NM_001145785:exon9:c.A937C:p.T313P,exonic,MEF2B;MEF2BNB-MEF2B,,nonsynonymous SNV,MEF2B:uc002nll.2:exon9:c.A937C:p.T313P;MEF2BNB-MEF2B:uc010xqp.1:exon13:c.A937C:p.T313P,,,,,,,,,,,,,,,,,,,0.19,,,,,,,,,0.005,B,0.005,B,0.249,0.902,10.09,0.847,0.079,0.02,0.441,0.104,T,.,.,.,1,0.09,N,.,.,.,-2.05,0.867,D,-1.39,0.344,N,-0.766,0.571,T,0.372,0.731,T,0.106,0.783,D,0.192,0.103,0.024,0.067,N,c,-0.938,-0.997,0.994,0.335,0.672,0.522,0,-2.88,0.053,-0.992,0.038,0.835,0.34,0,0.063,0.044,0.16,5.45,0.157,.,.,.,,,,,,,,,,,,,,,,,,,,,chr19,19256776,.,T,G,.,PASS,ADP=195;WT=0;HET=1;HOM=0;NC=0,GT:GQ:SDP:DP:RD:AD:FREQ:PVAL:RBQ:ABQ:RDF:RDR:ADF:ADR:FA,0/1:33:210:195:182:11:5.67%:4.2175E-4:29:20:155:27:10:1:0.0567
21,chr19,19256785,19256785,A,G,MEF2B,NM_001145785,c.928T>C,p.Ser310Pro,148,0.0743,IGV,,,,'15/293',,True,,,33,Exonic;VAF>=0.05;DP>=100,VarScan2,'15/293',0.0743;0.1053;0.1121;0.1829,SE20-3057_VEN-317-ARC-1_Hi5_AGXTHSv2;SE21-0234_VEN-325-ARC-1_Hi5_AGXTHSv2;SE21-0611_VEN-347-ARC-1_Hi5_AGXTHSv2;SE20-0652_VEN-261-ARC-1_Hi5_AGSSv2;SE21-1293_VEN-329-ARC-1_Hi5_AGXTHSv2;SE21-0237_VEN-335-ARC-1_Hi5_AGXTHSv2;SE21-0334_DIVA-414-BX-1_Hi5_AGXTHSv2;SE21-0578_VEN-341-ARC-1_Hi5_AGXTHSv2;SE21-1318_AMDL2021_Hi5-01_Hi5_AGXTHSv2;SE20-2861_DIVA-197-ARC-1_Hi5_AGXTHSv2;SE21-0945_VEN-337-ARC-1_Hi5_AGXTHSv2;SE21-0988_VEN-357-BX-1_Hi5_AGXTHSv2;SE21-0812_VEN-131-BX-2_Hi5_AGXTHSv2;SE21-0797_VEN-354-ARC-1_Hi5_AGXTHSv2;SE21-1294_VEN-335-ARC-1_Hi5_AGXTHSv2,'5/12',0.0743;0.1389;0.1294;0.1829,,problematic,MEF2B;NM_001145785.1;exon_9,exon9,exonic,,,,http://205.210.128.135:8000/gene/MEF2B/variant/p.Ser310Pro/result#report,,,MEF2B,,nonsynonymous SNV,MEF2B:NM_001145785:exon9:c.T928C:p.S310P,exonic,MEF2B;MEF2BNB-MEF2B,,nonsynonymous SNV,MEF2B:NM_001145785:exon9:c.T928C:p.S310P,exonic,MEF2B;MEF2BNB-MEF2B,,nonsynonymous SNV,MEF2B:uc002nll.2:exon9:c.T928C:p.S310P;MEF2BNB-MEF2B:uc010xqp.1:exon13:c.T928C:p.S310P,,,,,,,,,,,,,,,,,,,0.01,,,,,,,,,0.999,D,0.994,D,0.334,4.864,24.9,0.975,0.116,0.014,0.124,0.274,T,.,.,.,1,0.186,N,.,.,.,-2.09,0.866,D,-1.39,0.344,N,-0.197,0.778,T,0.694,0.894,D,0.758,0.981,D,0.254,0.194,0.411,0.263,N,c,-0.11,-0.176,0.996,0.345,0.672,0.522,0,3.13,0.349,0.657,0.245,0.066,0.173,0.08,0.221,0.057,0.169,6.809,0.228,.,.,.,,,,,,,,,,,,,,,,,,,,,chr19,19256785,.,A,G,.,PASS,ADP=148;WT=0;HET=1;HOM=0;NC=0,GT:GQ:SDP:DP:RD:AD:FREQ:PVAL:RBQ:ABQ:RDF:RDR:ADF:ADR:FA,0/1:33:178:148:136:11:7.43%:4.0216E-4:34:16:108:28:11:0:0.0743
22,chr20,60747833,60747833,T,C,SS18L1,NM_198935,c.1012T>C,p.Tyr338His,393,0.43,IGV,,,,'2/293',,True,,,255,Exonic;VAF>=0.05;DP>=100,VarScan2,'2/293',0.4268;0.4284;0.4284;0.43,SE21-1318_AMDL2021_Hi5-01_Hi5_AGXTHSv2;SE20-0964_VEN-264-ARC-1_Hi5_AGXTHSv2,'1/12',0.43;0.43;0.43;0.43,,,SS18L1;NM_198935.2;exon_9,exon9,exonic,,,,http://205.210.128.135:8000/gene/SS18L1/variant/p.Tyr338His/result#report,,,SS18L1,,nonsynonymous SNV,SS18L1:NM_198935:exon9:c.T1012C:p.Y338H,exonic,SS18L1,,nonsynonymous SNV,SS18L1:NM_198935:exon9:c.T1012C:p.Y338H;SS18L1:NM_001301778:exon10:c.T619C:p.Y207H,exonic,SS18L1,,nonsynonymous SNV,SS18L1:uc002ycb.3:exon9:c.T1012C:p.Y338H;SS18L1:uc011aaa.1:exon9:c.T1012C:p.Y338H,,,,,,,,,,,,,,,,,,,0,,,,,,,,,0.999,D,0.996,D,0.764,3.622,23.2,0.992,0.991,0.998,0.001,0.912,D,0,0.843,D,0.999,0.456,D,2.14,0.601,M,0.97,0.437,T,-2.21,0.543,N,-0.361,0.733,T,0.328,0.697,T,0.021,0.438,T,0.357,0.36,0.981,0.794,D,c,0.743,0.723,1,0.747,0.635,0.413,0,5.32,0.753,7.526,0.807,1.034,0.654,1,0.715,1,0.888,15.56,0.759,.,.,.,,,,,,,,,,,,,,,,,,,,,chr20,60747833,.,T,C,.,PASS,ADP=393;WT=0;HET=1;HOM=0;NC=0,GT:GQ:SDP:DP:RD:AD:FREQ:PVAL:RBQ:ABQ:RDF:RDR:ADF:ADR:FA,0/1:255:394:393:224:169:43%:1.0327E-61:55:64:189:35:129:40:0.4300
23,chrX,66765159,66765182,GCAGCAGCAGCAGCAGCAGCAGCA,-,AR,NM_000044,c.216_239delGCAGCAGCAGCAGCAGCAGCAGCA,p.Gln73_Gln80del,169,0.1243,IGV,,,,'5/293',,True,,,66,Exonic;VAF>=0.05;DP>=100,VarScan2,'5/293',0.1039;0.1429;0.1607;0.2296,SE21-0921_VEN-356-ARC-1_Hi5_AGXTHSv2;SE21-1318_AMDL2021_Hi5-01_Hi5_AGXTHSv2;SE21-0989_VEN-361-ARC-1_Hi5_AGXTHSv2;SE20-0964_VEN-264-ARC-1_Hi5_AGXTHSv2;SE20-3237_VEN-322-ARC-1_Hi5_AGXTHSv2,'2/12',0.1243;0.1636;0.1636;0.2029,,problematic,AR;NM_000044.3;exon_1,exon1,exonic,,,,http://205.210.128.135:8000/gene/AR/variant/p.Gln73_Gln80del/result#report,"Gene Role: Oncogene (PMID: 30606230);Highest Evidence Level: A;Highest Tier: I;AR, androgen receptor, belongs to the nuclear hormone receptor family, which acts as a transcription factor, resulting in either transcription or repression of specific genes (PMID: 24909511, PMID: 21784131). AR overexpression leads to ligand independent activation of AR and is common in prostate cancer (PMID: 16598769) and AR mutations and constitutively active splice variants are also commonly observed in prostate cancer (PMID: 31868960).",,AR,,nonframeshift deletion,AR:NM_000044:exon1:c.171_194del:p.57_65del,exonic,AR,,nonframeshift deletion,AR:NM_000044:exon1:c.171_194del:p.57_65del,exonic,AR,,nonframeshift deletion,AR:uc004dwu.2:exon1:c.171_194del:p.57_65del;AR:uc011mpd.2:exon1:c.171_194del:p.57_65del;AR:uc011mpf.1:exon1:c.171_194del:p.57_65del;AR:uc022byk.1:exon1:c.171_194del:p.57_65del,,,,,,,,,,,,,,,,,,,,,534907,Androgen_resistance_syndrome|Bulbo-spinal_atrophy_X-linked,"MedGen:C0039585,OMIM:300068,Orphanet:ORPHA754,SNOMED_CT:12313004|MedGen:C1839259,OMIM:313200,Orphanet:ORPHA481","criteria_provided,_single_submitter",Benign,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,chrX,66765158,.,TGCAGCAGCAGCAGCAGCAGCAGCA,T,.,PASS,ADP=169;WT=0;HET=1;HOM=0;NC=0,GT:GQ:SDP:DP:RD:AD:FREQ:PVAL:RBQ:ABQ:RDF:RDR:ADF:ADR:FA,0/1:66:177:169:133:21:12.43%:2.2955E-7:44:31:85:48:12:9:0.1243
24,chrX,66765182,66765182,A,T,AR,NM_000044,c.194A>T,p.Gln65Leu,147,0.0962,IGV,,,,'1/293',,True,,,31,Exonic;VAF>=0.05;DP>=100,VarScan2,'1/293',0.0962;0.0962;0.0962;0.0962,SE21-1318_AMDL2021_Hi5-01_Hi5_AGXTHSv2,'1/12',0.0962;0.0962;0.0962;0.0962,,problematic,AR;NM_000044.3;exon_1,exon1,exonic,,,,http://205.210.128.135:8000/gene/AR/variant/p.Gln65Leu/result#report,"Gene Role: Oncogene (PMID: 30606230);Highest Evidence Level: A;Highest Tier: I;AR, androgen receptor, belongs to the nuclear hormone receptor family, which acts as a transcription factor, resulting in either transcription or repression of specific genes (PMID: 24909511, PMID: 21784131). AR overexpression leads to ligand independent activation of AR and is common in prostate cancer (PMID: 16598769) and AR mutations and constitutively active splice variants are also commonly observed in prostate cancer (PMID: 31868960).",,AR,,nonsynonymous SNV,AR:NM_000044:exon1:c.A194T:p.Q65L,exonic,AR,,nonsynonymous SNV,AR:NM_000044:exon1:c.A194T:p.Q65L,exonic,AR,,nonsynonymous SNV,AR:uc004dwu.2:exon1:c.A194T:p.Q65L;AR:uc011mpd.2:exon1:c.A194T:p.Q65L;AR:uc011mpf.1:exon1:c.A194T:p.Q65L;AR:uc022byk.1:exon1:c.A194T:p.Q65L,,,,,,,,,,,,,,,,,,,0.05,ID=COSM3424904;OCCURENCE=1(large_intestine),,,,,,,,0.925,P,0.954,D,0.397,1.952,15.91,0.994,0,0.927,0.031,0.45,D,0.555,0.054,N,1,0.186,N,0.345,0.112,N,0.01,0.625,T,-0.82,0.225,N,-0.834,0.531,T,0.237,0.604,T,0.043,0.61,D,.,.,0.061,0.119,N,.,.,.,1,0.747,.,.,.,1.43,0.215,-0.649,0.054,0.384,0.275,0.201,0.241,0.977,0.48,4.865,0.129,Armadillo-like helical;WD40/YVTN repeat-like-containing domain,.,.,,,,,,,,,,,,,,,,,,,,,chrX,66765182,.,A,T,.,PASS,ADP=147;WT=0;HET=1;HOM=0;NC=0,GT:GQ:SDP:DP:RD:AD:FREQ:PVAL:RBQ:ABQ:RDF:RDR:ADF:ADR:FA,0/1:31:150:147:94:10:9.62%:7.7841E-4:41:30:51:43:9:1:0.0962
